ABSTRACT: Cytochrome P450 (CYP) 2S1 is "orphan" CYP that is overexpressed in several epithelial tissues and many human tumors. The pure enzyme is required for better understanding of its biological functions. Therefore, human CYP2S1 was considered to be prepared by the gene manipulations and heterologous expression in Escherichia coli. Here, the conditions suitable for efficient expression of human CYP2S1 protein from plasmid pCW containing the human CYP2S1 gene were optimized and the enzyme purified to homogeneity. The identity of CYP2S1 as the product of heterologous expression was confirmed by dodecyl sulfate-polyacrylamide gel electrophoresis, Western blotting, and mass spectrometry. To confirm the presence of the enzymatically active CYP2S1, the CO spectrum of purified CYP2S1 was recorded. Since CYP2S1 was shown to catalyze oxidation of compounds having polycyclic aromatic structures, the prepared enzyme has been tested to metabolize the compounds having this structural character; namely, the human carcinogen benzo[a]pyrene (BaP), its 7,8-dihydrodiol derivative, and an anticancer drug ellipticine. Reaction mixtures contained besides the test compounds the CYP2S1 enzyme reconstituted with NADPH:CYP reductase (POR) in liposomes, and/or this CYP in the presence of cumene hydroperoxide or hydrogen peroxide. High performance liquid chromatography was employed for separation of BaP, BaP-7,8-dihydrodiol, and ellipticine metabolites. The results found in this study demonstrate that CYP2S1 in the presence of cumene hydroperoxide or hydrogen peroxide catalyzes oxidation of two of the test xenobiotics, a metabolite of BaP, BaP-7,8-dihydrodiol, and ellipticine. Whereas BaP-7,8,9,10-tetrahydrotetrol was formed as a product of BaP-7,8-dihydrodiol oxidation, ellipticine was oxidized to 12-hydroxyellipticine, 13-hydroxyellipticine, and the ellipticine N2-oxide.

Analytical and Environmental Sciences Division MRC PHE Centre for Environment and Health King's College London London SE1 9NH UK

Department of Biochemistry Faculty of Science Charles University Albertov 2030 128 40 Prague 2 Czech Republic

Department of Chemistry and Biochemistry Faculty of Agronomy Mendel University in Brno 613 00 Brno Czech Republic

Department of Oncology 2nd Faculty of Medicine Charles University and University Hospital Motol 5 Uvalu 84 150 06 Prague 5 Czech Republic

Zobrazit více v PubMed

Guengerich FP. Chem Res Toxicol. 2001;14:611. doi: 10.1021/tx0002583. PubMed DOI

Guengerich FP. Chem Res Toxicol. 2008;21:70. doi: 10.1021/tx700079z. PubMed DOI

Arlt VM, Henderson CJ, Wolf CR, Stiborova M, Phillips DH. Toxicol Res. 2015;4:548. doi: 10.1039/C4TX00116H. DOI

Riddick DS, Ding X, Wolf CR, Porter TD, Pandey AV, Zhang QY, Gu J, Finn RD, Ronseaux S, McLaughlin LA, Henderson CJ, Zou L, Fluck CE. Drug Metab Disp. 2013;41:12. doi: 10.1124/dmd.112.048991. PubMed DOI PMC

Porter TD. J Biochem Mol Toxicol. 2002;16:311. doi: 10.1002/jbt.10052. PubMed DOI

Rendic S, Di Carlo FJ. Drug Metab Rev. 2007;29:413. doi: 10.3109/03602539709037591. PubMed DOI

Wienkers LC, Heath LC. Nat Rev Drug Dis. 2005;4:825. doi: 10.1038/nrd1851. PubMed DOI

Guengerich FP, Wu ZL, Bartleson CJ. Biochem Biophys Res Commun. 2005;338:465. doi: 10.1016/j.bbrc.2005.08.079. PubMed DOI

Wu ZL, Sohl CD, Shimada T, Guengerich FP. Mol Pharmacol. 2006;69:2007. doi: 10.1124/mol.106.023648. PubMed DOI

Bui PH, Hankinson O. Mol Pharmacol. 2009;76:1031. doi: 10.1124/mol.109.057752. PubMed DOI PMC

Bui PH, Hsu EL, Hankinson O. Mol Pharmacol. 2009;76:1044. doi: 10.1124/mol.109.057760. PubMed DOI PMC

Smith G, Wolf CR, Deeni YY, Dawe RS, Evans AT, Comrie MM, Ferguson J, Ibbotson SH. Lancet. 2003;361:1336. doi: 10.1016/S0140-6736(03)13081-4. PubMed DOI

Rivera SP, Wang F, Saarikoski ST, Taylor RT, Chapman B, Zhang R, Hankinson (2007) J Biol Chem 282:10881 PubMed

Bui P, Imaizumi S, Beedanagari SR, Reddy ST, Hankinson O. Drug Metab Dispos. 2011;39:180. doi: 10.1124/dmd.110.035121. PubMed DOI PMC

Xiao Y, Shinkyo R, Guengerich FP. Drug Metab Dispos. 2011;39:944. doi: 10.1124/dmd.111.039321. PubMed DOI PMC

International Agency for Research on Cancer (IARC) (2010). Some non-heterocyclic polycyclic aromatic hydrocarbons and some related exposures. In: IARC Monogr Eval Carcinog Risks Hum 92:1 PubMed PMC

Stiborová M, Rupertová M, Frei E. Biochim Biophys Acta. 2011;1814:175. doi: 10.1016/j.bbapap.2010.05.016. PubMed DOI

Stiborová M, Černá V, Moserová M, Mrízová I, Arlt VM, Frei E. Int J Mol Sci. 2015;16:284. doi: 10.3390/ijms16010284. PubMed DOI PMC

Stiborova M, Frei E. Curr Med Chem. 2014;21:575. doi: 10.2174/09298673113206660272. PubMed DOI

Stiborova M, Moserova M, Cerna V, Indra R, Dracinsky M, Šulc M, Henderson CJ, Wolf CR, Schmeiser HH, Phillips DH, Frei E, Arlt VM. Toxicology. 2014;318:1. doi: 10.1016/j.tox.2014.02.002. PubMed DOI

Arlt VM, Stiborova M, Henderson CJ, Thiemann M, Frei E, Aimova D, Singhs R, da Costa GG, Schmitz OJ, Farmer PB, Wolf CR, Philips DH. Carcinogenesis. 2008;29:656. doi: 10.1093/carcin/bgn002. PubMed DOI

Arlt VM, Poirier MC, Sykes SE, Kaarthik J, Moserova M, Stiborova M, Wolf R, Henderson CJ, Phillips DH. Toxicol Lett. 2012;213:160. doi: 10.1016/j.toxlet.2012.06.016. PubMed DOI PMC

Stiborová M, Arlt VM, Henderson CJ, Wolf CR, Kotrbová V, Moserová M, Hudecek J, Phillips DH, Frei E. Toxicol Appl Pharmacol. 2008;226:318. doi: 10.1016/j.taap.2007.09.017. PubMed DOI

Stiborova M, Moserova M, Mrazova B, Kotrbova V, Frei E. Neuro Endocrinol Lett. 2010;31(Suppl 2):26. PubMed

Hodek P, Hrdinova J, Macova I, Soucek P, Mrizova I, Burdova K, Kizek R, Hudecek J, Stiborova M. Neuro Endocrinol Lett. 2015;36(Suppl 1):38. PubMed

Kotrbova V, Mrazova B, Moserova M, Martinek V, Hodek P, Hudecek J, Frei E, Stiborova M. Biochem Pharmacol. 2011;82:669. doi: 10.1016/j.bcp.2011.06.003. PubMed DOI

Stiborova M, Indra R, Moserova M, Cerna V, Rupertova M, Martinek V, Eckschlager T, Kizek R, Frei E. Chem Res Toxicol. 2012;25:1075. doi: 10.1021/tx3000335. PubMed DOI

Stiborova M, Moserova M, Cerna V, Indra R, Dracinsky M, Šulc M, Henderson CJ, Wolf CR, Schmeiser HH, Phillips DH, Frei E, Arlt VM. Toxicology. 2014;318:1. doi: 10.1016/j.tox.2014.02.002. PubMed DOI

Baird WM, Hooven LA, Mahadevan B. Environ Mol Mutagen. 2005;45:106. doi: 10.1002/em.20095. PubMed DOI

Stiborová M, Sejbal J, Borek-Dohalská L, Aimová D, Poljaková J, Forsterová K, Rupertová M, Wiesner J, Hudecek J, Wiessler M, Frei E. Cancer Res. 2004;64:8374. doi: 10.1158/0008-5472.CAN-04-2202. PubMed DOI

Stiborová M, Poljaková J, Martínková E, Ulrichová J, Simánek V, Dvořák Z, Frei E. Toxicology. 2012;302:233. doi: 10.1016/j.tox.2012.08.004. PubMed DOI

Poljaková J, Frei E, Gomez JE, Aimová D, Eckschlager T, Hrabeta J, Stiborová M. Cancer Lett. 2007;252:270. doi: 10.1016/j.canlet.2006.12.037. PubMed DOI

Martinkova E, Dontenwill M, Frei E, Stiborova M. Neuro Endocrinol Lett. 2009;30(Suppl 1):60. PubMed

Bořek-Dohalská L, Frei E, Stiborová M. Collect Czech Chem Commun. 2004;69:603. doi: 10.1135/cccc20040603. DOI

Poljaková J, Eckschlager T, Hrabeta J, Hrebacková J, Smutný S, Frei E, Martínek V, Kizek R, Stiborová M. Biochem Pharmacol. 2009;77:1466. doi: 10.1016/j.bcp.2009.01.021. PubMed DOI

Stiborova M, Poljakova J, Mrizova LI, Borek-Dohalska L, Eckschlager T, Adam V, Kizek R, Frei E. Int J Electrochem Sci. 2014;9:5675.

Wohak LE, Krais AM, Kucab JE, Stertmann J, Øvrebø S, Seidel A, Phillips DH, Arlt VM. Arch Toxicol. 2014;90:291. doi: 10.1007/s00204-014-1409-1. PubMed DOI PMC

Hanna IH, Teiber JF, Kokones KL, Hollenberg PF. Arch Biochem Biophys. 1998;350:324. doi: 10.1006/abbi.1997.0534. PubMed DOI

Hanna IH, Reed JR, Guengerich FP, Hollenberg PF. Arch Biochem Biophys. 2000;376:206. doi: 10.1006/abbi.2000.1708. PubMed DOI

Culka M, Milichovsky J. Jerabek P, Stiborova M, Martinek V (2015) Neuro Endocrinol Lett 36 Suppl 1:29 PubMed

Shimada T, Wunsch RM, Hanna IH, Sutter TR, Guengerich FP, Gillam EMJ. Arch Biochem Biophys. 1998;357:111. doi: 10.1006/abbi.1998.0808. PubMed DOI

Guengerich FP, Martin MV. Methods Mol Biol. 2006;320:31. PubMed

Harnastai IN, Gilep AA, Usanov SA. Protein Expr Purif. 2006;46:47. doi: 10.1016/j.pep.2005.07.006. PubMed DOI

Lee SH, Yu HJ, Lee S, Ryu D-Y. Toxicol Lett. 2015;239:81. doi: 10.1016/j.toxlet.2015.09.007. PubMed DOI

Omura T, Sato R. J Biol Chem. 1964;239:2370. PubMed

Wiechelman KJ, Braun RD, Fitzpatrick JD. Anal Biochem. 1988;175:231. doi: 10.1016/0003-2697(88)90383-1. PubMed DOI

Stiborova M, Martinek V, Rydlova H, Hodek P, Frei E. Cancer Res. 2002;62:5678. PubMed

Stiborová M, Bieler CA, Wiessler M, Frei E. Biochem Pharmacol. 2001;62:1675. doi: 10.1016/S0006-2952(01)00806-1. PubMed DOI

Indra R, Moserova M, Kroftova N, Sulc M, Martinkova M, Adam V, Eckschlager T, Kizek R, Arlt VM, Stiborova M. Neuro Endocrinol Lett. 2014;35(Suppl 2):105. PubMed

Moserová M, Kotrbová V, Aimová D, Sulc M, Frei E, Stiborová M. Interdiscip Toxicol. 2009;2:239. doi: 10.2478/v10102-009-0024-0. PubMed DOI PMC

Ječmen T, Ptáčková R, Černá V, Dračínská H, Hodek P, Stiborová M, Hudeček J, Šulc M. Methods. 2015;89:128. doi: 10.1016/j.ymeth.2015.07.015. PubMed DOI

Cytochrome b5 plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine